Literature DB >> 3797115

Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure.

M Hallman, T A Merritt, M Pohjavuori, L Gluck.   

Abstract

The turnover and pool size of surfactant has been studied in animals, but there is little similar information in humans. In the present investigation lung effluent phospholipids were studied in 29 small preterm infants with severe RDS. Thirteen were treated with mechanical ventilation, and 16 additionally received natural human surfactant. The first dose (60 mg surfactant/kg body wt) was given between 2 and 10 h of age, and the surfactant was given again if there was an insufficient response. Together 260 aspirates, recovered during routine suctioning of the airways, were analyzed for phospholipids. Phosphatidylglycerol, present only in exogenous surfactant, was used as a specific marker to estimate the apparent pool size and the half-life of surfactant phospholipid. In addition, the saturated phosphatidylcholine/sphingomyelin ratios were correlated with the ventilatory index (mean airway pressure X fractional inspiratory oxygen/arterial oxygen tension). There was a linear correlation between the ventilatory index and the saturated phosphatidylcholine/sphingomyelin (r approximately -0.70) but no consistent correlation between the ventilatory index and the amount of phospholipids in the aspirate. The saturated phosphatidylcholine/sphingomyelin ratio increased during the surfactant-induced remission of respiratory failure, decreased during the recovery. The control infants tended to have lower saturated phosphatidylcholine/sphingomyelin ratios during the first week than the surfactant-treated infants.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3797115     DOI: 10.1203/00006450-198612000-00008

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  10 in total

Review 1.  Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome.

Authors:  T A Merritt; M Hallman; R Spragg; G P Heldt; N Gilliard
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

2.  In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.

Authors:  Francesca Ricci; Xabier Murgia; Roberta Razzetti; Nicola Pelizzi; Fabrizio Salomone
Journal:  Pediatr Res       Date:  2016-11-03       Impact factor: 3.756

3.  Turnover of exogenous artificial surfactant.

Authors:  M R Ashton; A D Postle; M A Hall; N C Austin; D E Smith; I C Normand
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

4.  Phosphatidylcholine composition of endotracheal tube aspirates of neonates and subsequent respiratory disease.

Authors:  M R Ashton; A D Postle; M A Hall; S L Smith; F J Kelly; I C Normand
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

Review 5.  The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections.

Authors:  SeungHye Han; Rama K Mallampalli
Journal:  Ann Am Thorac Soc       Date:  2015-05

Review 6.  The fate of exogenous surfactant in neonates with respiratory distress syndrome.

Authors:  M Hallman; T A Merritt; K Bry
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

7.  In vivo effect of pneumonia on surfactant disaturated-phosphatidylcholine kinetics in newborn infants.

Authors:  Maddalena Facco; Matteo Nespeca; Manuela Simonato; Ilena Isak; Giovanna Verlato; Gianluca Ciambra; Chiara Giorgetti; Virgilio P Carnielli; Paola E Cogo
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

8.  Quantitative lipidomic analysis of mouse lung during postnatal development by electrospray ionization tandem mass spectrometry.

Authors:  Srikanth Karnati; Vannuruswamy Garikapati; Gerhard Liebisch; Paul P Van Veldhoven; Bernhard Spengler; Gerd Schmitz; Eveline Baumgart-Vogt
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

9.  Goat lung surfactant for treatment of respiratory distress syndrome among preterm neonates: a multi-site randomized non-inferiority trial.

Authors:  Kajal Jain; Sushma Nangia; Vishnu Bhat Ballambattu; Venkataseshan Sundaram; M Jeeva Sankar; Siddharth Ramji; Sreenivas Vishnubhatla; Anu Thukral; Yogendra Kumar Gupta; Nishad Plakkal; Mangalabharathi Sundaram; Mamta Jajoo; Praveen Kumar; Kumutha Jayaraman; Ashish Jain; Arvind Saili; Anitha Murugesan; Deepak Chawla; Srinivas Murki; Ruchi Nanavati; Suman Rao; Umesh Vaidya; Ashish Mehta; Kamal Arora; Jayashree Mondkar; Sugandha Arya; Monika Bahl; Alpana Utture; Swati Manerkar; Swarna Rekha Bhat; Tushar Parikh; Manish Kumar; Anurag Bajpai; Sindhu Sivanandan; Pawandeep Kaur Dhawan; Gayatri Vishwakarma; Sudhakar Bangera; Sumit Kumar; Shridhar Gopalakrishnan; Atul Jindal; Chandra Kumar Natarajan; Anumeet Saini; Sukanya Karunanidhi; Meenakshi Malik; Parul Narang; Gurkirat Kaur; Chander Prakash Yadav; Ashok Deorari; Vinod K Paul; Ramesh Agarwal
Journal:  J Perinatol       Date:  2019-09       Impact factor: 2.521

Review 10.  Common respiratory conditions of the newborn.

Authors:  David J Gallacher; Kylie Hart; Sailesh Kotecha
Journal:  Breathe (Sheff)       Date:  2016-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.